High-flow nasal cannula (HFNC) systems employ different methods to provide aerosol to patients. This study compared delivery efficiency, particle size, and regional deposition of aerosolized bronchodilators during HFNC in neonatal, pediatric, and adult upper-airway and lung models between a proximal aerosol adapter and distal aerosol circuit chamber.
METHODS:
A filter was connected to the upper airway to a spontaneously breathing lung model. Albuterol was nebulized using the aerosol adapter and circuit at different clinical flow settings. The aerosol mass deposited in the upper airway and lung was quantified. Particle size was measured with a laser diffractometer. Regional deposition was assessed with a gamma camera at each nebulizer location and patient model with minimum flow settings.
RESULTS:
Inhaled lung doses ranged from 0.2–0.8% for neonates, 0.2–2.2% for the small child, and 0.5–5.2% for the adult models. Neonatal inhaled lung doses were not different between the aerosol circuit and adapter, but the aerosol circuit showed marginally greater lung doses in the pediatric and adult patient models. Impacted aerosols and condensation in the non-heated HFNC and aerosol delivery components contributed to the dispersion of coarse liquid droplets, high deposition (11–44%), and occlusion of the supine neonatal upper airway. In contrast, the upright pediatric and adult upper-airway models had minimal deposition (0.3–7.0%) and high fugitive losses (∼24%) from liquid droplets leaking out of the nose. The high impactive losses in the aerosol adapter (56%) were better contained than in the aerosol circuit, resulting in less cannula sputter (5% vs 22%), fewer fugitive losses (18% vs 24%), and smaller inhaled aerosols (5 m vs 13 m).
CONCLUSIONS:
The inhaled lung dose was low (1–5%) during HFNC. Approaches that streamline aerosol delivery are needed to provide safe and effective therapy to patients receiving aerosolized medications with this HFNC system.
Al-AlaiyanS, DawoudM, Al-HazzaniF. Positive distending pressure produced by heated, humidified high-flow nasal cannula as compared to nasal continuous positive airway pressure in premature infants. J Neonatal Perinatal Med, 2014; 7(2):119-124.
2.
DysartK, MillerTL, WolfsonMR, ShafferTH. Research in high-flow therapy: mechanisms of action. Respir Med, 2009; 103(10):1400-1405.
3.
IyerNP, MhannaMJ. Association between high-flow nasal cannula and end-expiratory esophageal pressures in premature infants. Respir Care, 2016; 61(3):285-290.
4.
NielsenKR, EllingtonLE, GrayAJ, StanberryLI, SmithLS, DiBlasiRM. Effect of high-flow nasal cannula on expiratory pressure and ventilation in infant, pediatric, and adult models. Respir Care, 2018; 63(2):147-157.
5.
JeongJH, KimDH, KimSC, KangC, LeeSH, KangTS, et al. Changes in arterial blood gases after use of high-flow nasal cannula therapy in the ED. American J Emerg Med, 2015; 33(10):1344-1349.
6.
MauriT, TurriniC, EroniaN, GrasselliG, VoltaCA, BellaniG, et al. Physiologic effects of high-flow nasal cannula in acute hypoxemic respiratory failure. Am J Respir Crit Care Med, 2017; 195(9):1207-1215.
7.
WeilerT, KamerkarA, HotzJ, RossPA, NewthCJL, KhemaniRG. The relationship between high-flow nasal cannula flow rate and effort of breathing in children. J Pediatr, 2017; 189:66-71.e3. e63.
8.
KugelmanA, RiskinA, SaidW, ShorisI, MorF, BaderD. A randomized pilot study comparing heated humidified high-flow nasal cannulae with NIPPV for RDS. Pediatr Pulmonol, 2015; 50(6):576-583.
9.
SunJ, LiY, LingB, ZhuQ, HuY, TanD, et al. High-flow nasal cannula oxygen therapy versus noninvasive ventilation for chronic obstructive pulmonary disease with acute-moderate hypercapnic respiratory failure: an observational cohort study. COPD, 2019; 14:1229-1237.
10.
ColettiKD, BagdureDN, WalkerLK, RemyKE, CusterJW. High-flow nasal cannula utilization in pediatric critical care. Respir Care, 2017; 62(8):1023-1029.
11.
DaileyPA, HarwoodR, WalshK, FinkJB, ThayerT, GagnonG, et al. Aerosol delivery through adult high-flow nasal cannula with heliox and oxygen. Respir Care, 2017; 62(9):1186-1192.
12.
AriA. Effect of nebulizer type, delivery interface, and flow rate on aerosol drug delivery to spontaneously breathing pediatric and infant lung models. Pediatr Pulmonol, 2019; 54(11):1735-1741.
13.
LiJ, AAA, LJH, FinkJB, DhandR. Mitigating fugitive aerosols during aerosol delivery via high-flow nasal cannula devices. Respir Care, 2022; 67(4):404-414.
14.
LiJ, FinkJB, MacLoughlinR, DhandR. A narrative review on transnasal pulmonary aerosol delivery. Crit Care, 2020; 24(1):506-506.
15.
LiJ, TuM, YangL, JingG, FinkJB, BurtinC, et al. Worldwide clinical practice of high-flow nasal cannula and concomitant aerosol therapy in the adult ICU setting. Respir Care, 2021; 66(9):1416-1424.
16.
RéminiacF, VecellioL, LoughlinRM, Le PennecD, CabreraM, Vourc’hNH, et al. Nasal high-flow nebulization in infants and toddlers: an in vitro and in vivo scintigraphic study. Pediatr Pulmonol, 2017; 52(3):337-344.
17.
AlcoforadoL, AriA, BarcelarJ, BrandãoS, FinkJ, Dornelas de AndradeA. Impact of gas flow and humidity on transnasal aerosol deposition via nasal cannula in adults: a randomized crossover study. Pharmaceutics, 2019; 11(7):320.
18.
DugernierJ, HesseM, JumetzT, BialaisE, RoeselerJ, DepoortereV, et al. Aerosol delivery with two nebulizers through high-flow nasal cannula: a randomized crossover single-photon emission computed tomography-computed tomography study. J Aerosol Med Pulm Drug Deliv, 2017; 30(5):349-358.
19.
Al-SubuAM, HagenS, EldridgeM, BoriosiJ. Aerosol therapy through high-flow nasal cannula in pediatric patients. Expert Rev Respir Med, 2017; 11(12):945-953.
20.
Al-SubuAM, NguyenVT, AlAliY, Yngsdal-KrenzRA, LasarevMR, EldridgeMW, et al. Feasibility of aerosol bronchodilators delivery through high-flow nasal cannula in pediatric subjects with respiratory distress. Respir Care, 2020; 65(10):1464-1469.
21.
HessDR. Aerosol therapy during noninvasive ventilation or high-flow nasal cannula. Respir Care, 2015; 68(6):821-837. discussion 891–883.
22.
MillerAG, GentleMA, TylerLM, NapolitanoN. High-flow nasal cannula in pediatric patients: a survey of clinical practice. Respir Care, 2018; 63(7):894-899.
23.
LiJ, GongL, FinkJB. The ratio of nasal cannula gas flow to patient inspiratory flow on transnasal pulmonary aerosol delivery for adults: an in vitro study. Pharmaceutics, 2019; 11(5).
24.
LiJ, GongL, AriA, FinkJB. Decrease the flow setting to improve transnasal pulmonary aerosol delivery via “high-flow nasal cannula” to infants and toddlers. Pediatr Pulmonol, 2019; 54(6):914-921.
25.
KesavanS, AmiravI. Is aerosol delivery by high-flow nasal cannula in children an effective alternative to face mask aerosol nebulization?. Pediatr Pulmonol, 2019; 54(12):1873-1874.
26.
DoshiPB, WhittleJS, DunganG, VolakisLI, BublewiczM, KearneyJ, et al. The ventilatory effect of high-velocity nasal insufflation compared to noninvasive positive-pressure ventilation in the treatment of hypercapnic respiratory failure: a subgroup analysis. Heart Lung, 2020; 49(5):610-615.
27.
PerrySA, KesserKC, GellerDE, SelhorstDM, RendleJK, HertzogJH. Influences of cannula size and flow rate on aerosol drug delivery through the Vapotherm humidified high-flow nasal cannula system. Pediatr Crit Care Med, 2013; 14(5):e250-256-e256.
28.
DiBlasiRM, CoppoloDP, NagelMW, DoyleCC, AvvakoumovaVI, AliRS, et al. A novel, versatile valved holding chamber for delivering inhaled medications to neonates and small children: laboratory simulation of delivery options. Respir Care, 2010; 55(4):419-426.
29.
WuG, WollenA, DiBlasiRM, HimleyS, SaxonE, AustinG, et al. Reservoir cannulas for pediatric oxygen therapy: a proof-of-concept study. Int J Pediatr, 2016; 2016:9214389.
30.
HislopAA, HaworthSG. Airway size and structure in the normal fetal and infant lung and the effect of premature delivery and artificial ventilation. Am Rev Respir Dis, 1989; 140(6):1717-1726.
31.
NumaAH, NewthCJ. Anatomic dead space in infants and children. J Appl Physiol (1985), 1996; 80(5):1485-1489.
32.
CoffeyPS, SaxonEA, NarayananI, DiBlasiRM. Performance and acceptability of two self-inflating bag-mask neonatal resuscitator designs. Respir Care, 2015; 60(9):1227-1237.
33.
DiBlasiRM, CrotwellDN, ShenS, ZhengJ, FinkJB, YungD. Iloprost drug delivery during infant conventional and high-frequency oscillatory ventilation. Pulm Circ, 2016; 6(1):63-69.
34.
StocksJ, HislopAA. Structure and function of the respiratory system. Drug delivery to the lung. New York: Marcel Dekker Inc; 2002:47-104.
35.
JauernigJ, MitchellJ, BergE, DennisJ, KreherC, LambP, et al. Position paper: recommendation on the adoption of breathing patterns for infants and small children in general chapter 2.9.44. Preparations for nebulization. Pharmeur Sci Notes, 2008; 2008(1):31-32.
36.
MikalsenIB, DavisP, OymarK. High-flow nasal cannula in children: a literature review. Scand J Trauma Resusc Emerg Med, 2016; 24:93.
37.
SongX, HuJ, ZhanS, ZhangR, TanW. Effects of temperature and humidity on laser diffraction measurements to jet nebulizer and comparison with NGI. AAPS PharmSciTech, 2016; 17(2):380-388.
38.
RicciF, MersanneA, StortiM, NutiniM, PellicelliG, CariniA, et al. Preclinical assessment of nebulized surfactant delivered through neonatal high-flow nasal cannula respiratory support. Pharmaceutics, 2022; 14(5).
39.
SunbulFS, FinkJB, HarwoodR, SheardMM, ZimmermanRD, AriA. Comparison of HFNC, bubble CPAP, and SiPAP on aerosol delivery in neonates: an in vitro study. Pediatr Pulmonol, 2015; 50(11):1099-1106.
40.
SeifelnasrA, TalaatM, RamaswamyP, SiXA, XiJ. A supine position and dual-dose applications enhance spray dosing to the posterior nose: paving the way for mucosal immunization. Pharmaceutics, 2023; 15(2).
41.
FlinkRC, van KaamAH, de JonghFH. A humidifier in the invasive mode during noninvasive respiratory support could increase condensation and thereby impair airway patency. Acta Paediatr, 2018; 107(11):1888-1892.
42.
YoungquistTM, RichardsonCP, DiblasiRM. Effects of condensate in the exhalation limb of neonatal circuits on airway pressure during bubble CPAP. Respir Care, 2013; 58(11):1840-1846.
43.
AriA, HarwoodR, SheardM, DaileyP, FinkJB. In vitro comparison of heliox and oxygen in aerosol delivery using pediatric high-flow nasal cannula. Pediatr Pulmonol, 2011; 46(8):795-801.
44.
ReminiacF, VecellioL, Heuze-Vourc’hN, PetitcollinA, RespaudR, CabreraM, et al. Aerosol therapy in adults receiving high-flow nasal cannula oxygen therapy. J Aerosol Med Pulm Drug Deliv, 2016; 29(2):134-141.
45.
BlackburnMB, WangSC, RossBE, HolcombeSA, KempskiKM, BlackburnAN, et al. Anatomic accuracy of airway training manikins compared with humans. Anaesthesia, 2021; 76(3):366-372.
46.
GallagherL, JoyceM, MurphyB, Mac Giolla EainM, MacLoughlinR. The impact of head model choice on the in vitro evaluation of aerosol drug delivery. Pharmaceutics, 2022; 14(1):24.
47.
HosseiniS, GolshahiL. An in vitro evaluation of importance of airway anatomy in subregional nasal and paranasal drug delivery with nebulizers using 3 different anatomical nasal airway replicas of 2-, 5- and 50-year old human subjects. Int J Pharm, 2019; 563:426-436.
48.
XiJ, LongestPW, MartonenTB. Effects of the laryngeal jet on nanoparticle and microparticle transport and deposition in an approximate model of the upper tracheobronchial airways. J Appl Physiol (1985), 2008; 104(6):1761-1777.
49.
ClarkAR. Essentials for aerosol delivery to term and pre-term infants. Ann Transl Med, 2021; 9(7):594.
50.
BecqueminMH, SwiftDL, BouchikhiA, RoyM, TeillacA. Particle deposition and resistance in the noses of adults and children. Eur Respir J, 1991; 4(6):694-702.
51.
CorcoranTE, SavilleA, AdamsPS, JohnstonDJ, CzachowskiMR, DomninaYA, et al. Deposition studies of aerosol delivery by nasal cannula to infants. Pediatr Pulmonol, 2019; 54(8):1319-1325.
52.
MollerW, CelikG, FengS, BartensteinP, MeyerG, OliverE, et al. Nasal high-flow clears anatomical dead space in upper-airway models. J Appl Physiol (1985), 2015; 118(12):1525-1532.
FanJ, WilsonMC, KapurN. Displacement of liquid droplets on a surface by a shearing air flow. J Colloid Interface Sci, 2011; 356(1):286-292.
55.
LiJ, WeiW, FinkJB. In vitro comparison of unit dose vs infusion pump administration of albuterol via high-flow nasal cannula in toddlers. Pediatr Pulmonol, 2020; 55(2):322-329.
56.
XiJ, SiX, ZhouY, KimJ, BerlinskiA. Growth of nasal and laryngeal airways in children: implications in breathing and inhaled aerosol dynamics. Respir Care, 2014; 59(2):263-273.
57.
ZainudinBM, BiddiscombeM, TolfreeSE, ShortM, SpiroSG. Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurized metered dose inhaler, as a dry powder, and as a nebulized solution. Thorax, 1990; 45(6):469-473.
